Table 1.
Clinicopathological Features of MALT Lymphoma Patients
| Case | Age (years) | Sex | Origin | Histology | Stage | Other sites of involvement | Karyotype | RT-PCR product |
|---|---|---|---|---|---|---|---|---|
| 1* | 45 | F | Lung | LG | IVA | Hilar LN, Pleural effusion | 46,XX,t(11;18)(q21;q21) | + |
| 2* | 51 | M | Lung | LG | IA | — | 46,XY,t(11;18)(q21;q21) | + |
| 3* | 63 | F | Lung | LG | IA | — | 46,XX,t(11;18)(q21;q21), inv(16)(p13q22) | + |
| 4* | 45 | M | Colon | LG+H | IIA | Mesenteric LN | 46,XY,t(11;18)(q21;q21) | + |
| 5* | 56 | M | Colon | LG | IA | — | 46,XY,t(11;18)(q21;q21) | + |
| 6 | 61 | M | Lung | LG | IIA | Orbit | N.A. | − |
| 7 | 76 | M | Lung | LG | IA | — | N.A. | + |
| 8 | 63 | F | Lung | LG | IA | — | N.A. | + |
| 9 | 56 | M | Lung | LG | IIA | Salivary gland | N.A. | − |
| 10 | 74 | F | Lung | LG | IA | — | N.A. | − |
| 11 | 57 | F | Lung | LG | IA | — | N.A. | − |
| 12 | 72 | F | Stomach | LG+H | IIA | Gastric LN | N.A. | − |
| 13 | 39 | M | Stomach | LG | IA | — | N.A. | + |
| 14 | 38 | M | Stomach | LG | IA | — | N.A. | − |
| 15 | 67 | M | Stomach | LG+H | IIIA | Paratracheal LN Retroperitoneal LN | N.A. | − |
| 16 | 54 | F | Stomach | LG | IA | — | N.A. | − |
| 17 | 46 | M | Stomach | LG | IA | — | N.A. | − |
| 18 | 60 | F | Stomach | LG | IA | — | N.A. | − |
| 19 | 45 | F | Stomach | LG | IA | — | N.A. | − |
| 20 | 27 | M | Stomach | LG+H | IA | — | N.A. | − |
| 21 | 54 | F | Stomach | LG+H | IIA | Gastric LN | N.A. | − |
| 22 | 63 | M | Stomach | HG+L | IVA | Testis, Orbit Retroperitoneal LN | N.A. | − |
*Cases 1 through 5 are identical to the cases previously studied. 18
LG, low grade; LG+H, low grade with partially high grade component; HG+L, high grade with residual low grade component; LN, lymph node; N.A., not available.